CAS 865759-25-7|Trelagliptin

Introduction：Basic information about CAS 865759-25-7|Trelagliptin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Trelagliptin BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Trelagliptin
CAS Number	865759-25-7	Molecular Weight	357.382
Density	1.4±0.1 g/cm3	Boiling Point	519.0±60.0 °C at 760 mmHg
Molecular Formula	C₁₈H₂₀FN₅O₂	Melting Point	/
MSDS	/	Flash Point	267.7±32.9 °C

Names

Name	2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile
Synonym	More Synonyms

Trelagliptin BiologicalActivity

Description	Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.
Related Catalog	Signaling Pathways >>Metabolic Enzyme/Protease >>Dipeptidyl PeptidaseResearch Areas >>Metabolic Disease
References	[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus [2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus [3]. Long-term Study of SYR-472 [4]. SYR-472 Open-label Study

Description

Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.

Related Catalog

Signaling Pathways >>Metabolic Enzyme/Protease >>Dipeptidyl PeptidaseResearch Areas >>Metabolic Disease

References

[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

[2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

[3]. Long-term Study of SYR-472

[4]. SYR-472 Open-label Study

Chemical & Physical Properties

Density	1.4±0.1 g/cm3
Boiling Point	519.0±60.0 °C at 760 mmHg
Molecular Formula	C₁₈H₂₀FN₅O₂
Molecular Weight	357.382
Flash Point	267.7±32.9 °C
Exact Mass	357.160095
PSA	97.05000
LogP	1.88
Vapour Pressure	0.0±1.4 mmHg at 25°C
Index of Refraction	1.646
InChIKey	IWYJYHUNXVAVAA-OAHLLOKOSA-N
SMILES	Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O
Storage condition	-20°C
Water Solubility	Practically insoluble (0.034 g/L) (25 ºC)

Synonyms

Trelagliptin (USAN)

2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorobenzonitrile

Trelagliptin

UNII-Q836OWG55H

Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluoro-

SYR 472

Recommended......